In the ITT population, ivonescimab demonstrated a clinically meaningful mPFS of 11.15 months vs. 5.82 months with pembrolizumab in 1L PD-L1 positive advanced NSCLC.ITT Stratified HR: Ivonescimab ...
Some results have been hidden because they may be inaccessible to you